Level C· Early human research exploring benefitsProspective StudyPubMed

Native-Osteoarthritic Joint Resident Stem and Progenitor Cells for Cartilage Cell-Based Therapies: A Quantitative Comparison With Respect to Concentration and Biological Performance.

Mantripragada VP., Bova WA., Piuzzi NS., Boehm C., Obuchowski NA., Midura RJ.

Prospective Study with a reported sample of 6 on Osteoarthritis, Cartilage Damage, published in Am J Sports Med (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Am J Sports Med (2019)
Country
United States
Reported sample size
6
Source database
PubMed
PMID
31671273
DOI
10.1177/0363546519880905

Abstract (original English)

Cell-based therapy for cartilage repair is a promising approach and is becoming an established technique. Yet, there is no consensus on the optimal cell source. To provide a donor-matched quantitative comparison of the connective tissue progenitors (CTPs) derived from cartilage (Outerbridge grade 1-3 [G1-2-3]), bone marrow aspirate concentrate (BMC), infrapatellar fat pad (IPFP), synovium, and periosteum with respect to (1) cell concentration ([Cell], cells/mL), (2) CTP prevalence (P CTP , colonies per million cells), and (3) biological performance based on in vitro proliferation potential (cells per colony) colony density, and differentiation potential (expression of negatively charged extracellular matrix: glycosaminoglycan-rich extra cellular matrix [GAG-ECM]). Descriptive laboratory study. Tissues were obtained from 10 patients undergoing total knee arthroplasty (mean age, 59 years; women, n = 6). Automated quantitative colony-forming unit analysis was used to compare [Cell], P CTP , and CTP biological performance across tissue sources. [Cell] was highest in grade 3 cartilage ( P = .002) and BMC ( P = .001). Median P CTP was highest in IPFP ( P = .001), synovium ( P = .003), and G1-2 cartilage ( P = .02). Proliferation was highest in synovium-derived CTPs ( P < .001). Median colony density was highest in G1-2-3 ( P < .001). Median GAG-ECM was highest in G1-2-3 ( P < .001).

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueCartilageCell DifferentiationCells, CulturedExtracellular MatrixFemaleHematopoietic Stem Cell TransplantationHumansKnee JointMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research